AbstractGene delivery systems (GDS) play a central role in the development of gene therapy strategies for Cystic Fibrosis (CF). Further, these systems are important tools in studies with cultured cells and in animal models. In this review, we describe the properties of several viral and synthetic gene delivery systems, and evaluate their possible application in gene therapy of CF. While many gene delivery systems give satisfactory results in cultured or animal studies, none of these systems has been shown to fulfil all the requirements of safety and efficacy for use in CF patients. The intact airway epithelium, the most important target in CF gene therapy, proves to be well protected against invading vector systems
Cystic Fibrosis (CF) is an autosomal recessive disorder due to mutations in the CF transmembrane con...
Abstract: Cystic fibrosis (CF) is caused by mutations of the CF transmembrane conductance regulator ...
We use both large and small animal models in our pre-clinical evaluation of gene transfer agents (GT...
AbstractGene delivery systems (GDS) play a central role in the development of gene therapy strategie...
Gene therapy has been proposed for a wide range of human diseases but few have received the level of...
AbstractClinical trials in cystic fibrosis (CF) patients established proof-of-principle for transfer...
Since the discovery of the CFTR gene in 1989, many efforts have been made to develop an efficacious ...
Abstract The identification of the cystic fibrosis (CF) gene opened the way for gene therapy. In the...
Clinical trials in cystic fibrosis (CF) patients established proof-of-principle for transfer of the ...
Since the discovery of the CFTR gene, researchers have been working to develop a gene therapy techni...
Clinical trials in cystic fibrosis (CF) patients established proof-of-principle for transfer of the ...
Gene therapy is being developed as a novel treatment for cystic fibrosis (CF), a condition that has ...
Cystic fibrosis (CF) was one of the first inherited disorders for which gene therapy was seriously c...
Cystic fibrosis (CF) is caused by mutations of the CF transmembrane conductance regulator (CFTR) gen...
A gene therapy for cystic fibrosis (CF) lung disease by intralumenal delivery of therapeutic transge...
Cystic Fibrosis (CF) is an autosomal recessive disorder due to mutations in the CF transmembrane con...
Abstract: Cystic fibrosis (CF) is caused by mutations of the CF transmembrane conductance regulator ...
We use both large and small animal models in our pre-clinical evaluation of gene transfer agents (GT...
AbstractGene delivery systems (GDS) play a central role in the development of gene therapy strategie...
Gene therapy has been proposed for a wide range of human diseases but few have received the level of...
AbstractClinical trials in cystic fibrosis (CF) patients established proof-of-principle for transfer...
Since the discovery of the CFTR gene in 1989, many efforts have been made to develop an efficacious ...
Abstract The identification of the cystic fibrosis (CF) gene opened the way for gene therapy. In the...
Clinical trials in cystic fibrosis (CF) patients established proof-of-principle for transfer of the ...
Since the discovery of the CFTR gene, researchers have been working to develop a gene therapy techni...
Clinical trials in cystic fibrosis (CF) patients established proof-of-principle for transfer of the ...
Gene therapy is being developed as a novel treatment for cystic fibrosis (CF), a condition that has ...
Cystic fibrosis (CF) was one of the first inherited disorders for which gene therapy was seriously c...
Cystic fibrosis (CF) is caused by mutations of the CF transmembrane conductance regulator (CFTR) gen...
A gene therapy for cystic fibrosis (CF) lung disease by intralumenal delivery of therapeutic transge...
Cystic Fibrosis (CF) is an autosomal recessive disorder due to mutations in the CF transmembrane con...
Abstract: Cystic fibrosis (CF) is caused by mutations of the CF transmembrane conductance regulator ...
We use both large and small animal models in our pre-clinical evaluation of gene transfer agents (GT...